Outlook Therapeutics has re-submitted its Biologics License Application (BLA) to the US Food and Drug Administration (FDA) ...

Pivotal Phase 2b clinical trial (ELPIS II) evaluating Lomecel-B (laromestrocel) in Hypoplastic Left Heart Syndrome (HLHS), a rare pediatric disease and orphan-designated indication, has achieved more ...

Culver City, California Saturday, March 1, 2025, 17:00 Hrs [IST] ...

Presented positive interim data through 52 weeks and beyond for 4D-150 in wet AMD from PRISM Phase 1/2 clinical trial highlighting robust and durable clinical activity across diverse patient populatio ...

RCKT incurs a narrower-than-expected fourth-quarter 2024 loss. The company provides updates on its pipeline candidates.

Q4 2024 Earnings Call Transcript February 28, 2025 Amneal Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS ...

DNLI reports a narrower-than-expected loss for the fourth quarter of 2024. Denali remains on track to submit a BLA for ...

An international student has displayed the messages a man in his 40s sent her on WhatsApp because she rejected him. The ...

Goldman Sachs analyst Richard Law lowered the firm’s price target on Rocket Pharmaceuticals (RCKT) to $15 from $29 and keeps a Neutral rating ...

Throughout 2024, we continued to advance the development of our investigational cellular therapy candidate, Lomecel-B, as a potential ...

The FDA granted RMAT designation to nogapendekin alfa and CAR-NK for reversing lymphopenia in patients with cancer, with ...